Quantcast

Baltimore-based Cerecor obtains depression drug rights

Cerecor Inc., of Baltimore, a biopharmaceutical company focused on developing and commercializing prescription drugs involving the human nervous system, said it has acquired from Merck & Co. the exclusive, worldwide rights to a drug called MK-0657, which it said has the potential to treat depression. Merck originally developed MK-0657 for treatment of Parkinson’s disease.

Leave a Reply

Your email address will not be published. Required fields are marked *

*